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Studies determined the effects of chronic changes in sodium
diet on the expression, regulation, and function of different
angiotensin II (ANG II) receptor subtypes in renal resis-
tance vessels. Rats were fed low- or high-sodium diets for
3 wk before study. Receptor function was assessed in vivo
by measuring transient renal blood flow responses to bolus
injections of ANG II (2 ng) into the renal artery. ANG II
produced less pronounced renal vasoconstriction in rats fed
a low- compared with high-sodium diet (16% vs. 56% de-








 0.001). After acute blockade
of ANG II formation by iv enalaprilat injection in sodium-
restricted animals, ANG II produced a 40% decrease in re-
nal blood flow, a level between untreated dietary groups and
less than high salt diet. Intrarenal administration of angio-




) receptor antagonists losartan
or EXP–3174 simultaneously with ANG II caused dose-
dependent inhibition of ANG II responses. Based on maxi-





 receptor antagonists produced the same
degree of blockade in all groups, with an apparent maxi-
mum of 80–90%. In contrast, similar doses of the angioten-




) receptor ligand CGP-42112 had




I-ANG II binding studies on freshly isolated afferent arte-
rioles indicated that ANG II receptor density was lower








 0.04); affinity was similar (0.65 nM). Losartan and
EXP-3174 displaced up to 80–90% of the ANG II binding;





 receptor analogues PD-123319 and CGP-










 M had no effect on ANG II
binding. RT-PCR assays revealed the expression of both an-




) and angiotensin II re-




) subtypes in freshly isolated afferent









 receptor mRNA expression was suppressed
by low sodium intake to 66% of control levels, whereas it was
increased to 132% of control by high-sodium diet, as indi-
cated by ribonuclease protection assay. Receptor regulation






















 receptors are the predominant ANG II re-
ceptor type in renal resistance vessels of 7-wk–old rats.
Chronic changes in sodium intake caused parallel regula-





 receptor genes that modulate receptor function and al-



































































 is a potent vasoconstrictor that
exerts its biological actions after binding to cell surface recep-
tors and activating several signaling pathways that increase
intracellular calcium concentration and stimulate excitation–
contraction. Most of the effects of ANG II in the renal and car-










present in preglomerular arteries and arterioles, glomeruli,
vasa rectae, and proximal convoluted tubules. The major re-









 receptors is observed in young, developing ani-
mals (5).
Our previous studies on ANG II receptors and vascular
reactivity in rats on a normal salt diet indicate that ANG II pri-




 receptors and that such ligand–receptor





mediate a majority of the binding and functional response in





 receptors produce contraction of renal re-
sistance vessels by a combination of calcium entry through
L-type calcium channels, calcium mobilization from internal
stores, and activation of protein kinase C (7, 8).
Reactivity to ANG II in different vascular beds varies with
sodium intake, activity of the renin-angiotensin system in
healthy animals, and during different pathological states. It is
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well known that renal vascular reactivity to ANG II is exagger-
ated when endogenous ANG II plasma concentrations are
low, and vice versa (9, 10). The reasons for the differences in
vascular reactivity are likely to be multifaceted. Postulates in-
clude the abundance of cell surface receptors available to bind




 receptor coupling with second
messenger signals leading to tension and vasomotor tone.
ANG II receptors frequently, but not always, exhibit physi-
ological adaptation, and respond to chronic changes in sodium
diet and associated changes in renin-angiotensin system activ-
ity. Previous studies have used glomeruli and cultured mesan-
gial cells as models of vascular smooth muscle cells. Reciprocal
changes in salt intake and ANG II receptor density in rat
glomeruli has been reported (11–13), although this is not a uni-
versal finding (14). The changes correlated with plasma ANG
II concentration and similar responses are elicited by ANG II
infusion, implicating ANG II as the important regulator (12,
15). A similar pattern of downregulation of ANG II receptors
by ANG II or low-salt diet has been reported in vascular
smooth muscle cells from the mesenteric artery (16–19). In
marked contrast, a low-salt diet leads to an increase in ANG II
binding to renal cortical basolateral membranes (presumably
most of proximal tubular origin) freshly isolated proximal
tubular cells, and also in cultured proximal tubular cells (2, 20,
21). Upregulation of ANG II receptors is also observed in the
adrenal gland (18, 22, 23). In cultured mesangial cells, ANG II
is reported to down-regulate ANG II receptors, although
other investigators have found no effect on ANG II binding
sites (24, 25). Little is known about the regulation of ANG II
receptors in resistance vessels within the renal microcircula-
tion—in particular the afferent arterioles—and small arterioles
in other vascular beds. The reported changes in receptor den-
sity and binding characteristics may reflect changes involving
synthesis of different subtypes and/or subsequent processing.
The present studies investigated the influence of chronic
changes in sodium diet on the expression and function of ANG
II receptors in renal resistance vessels. We used RT-PCR and
ribonuclease protection assay and ANG II binding assay to
quantify ANG II receptor gene and protein expression. The









 receptor density in afferent arterioles isolated
from kidneys of animals maintained 3 wk on a high-sodium









) mRNA was independent
of salt intake, reflecting parallel change in response to salt-
induced changes in the renin–angiotensin system. The func-
tional correlate of receptor density was evaluated by assessing
in vivo reactivity of renal arterioles to ANG II. Renal vascular
reactivity to injection of ANG II into the renal artery was in-
versely related to salt diet. Inhibition with enalaprilat in low-
sodium animals revealed that part of the attenuated response
to administered ANG II was due to prior receptor occupation
by endogenous ANG II in addition to the observed changes in




Renal blood flow studies.
 
Experiments were performed on male,
7-wk–old anesthetized Wistar-Kyoto rats obtained from the Chapel
Hill breeding colony. The animals were maintained for 3 wk on Har-
lan rat chow balanced in all respects except for a high-sodium (3.2%)
or low-sodium (0.08%) content; tap water was allowed ad libitum.
An animal was deprived of food but not water the night before an
experiment. Standard surgical techniques were employed (6–8, 26).
Anesthesia was induced by an intraperitoneal injection of sodium
pentobarbital (65 mg/kg body wt), and the animals were placed on a





C. A tracheostomy was performed to facilitate free breathing. The
right carotid artery was cannulated to obtain blood samples, and to
monitor arterial pressure (P23Db transducer; Statham Instruments,
PR). The right jugular vein was cannulated for the administration of
maintenance infusions, cyclooxygenase inhibitor, and supplemental
doses of sodium pentobarbital. Isoncotic bovine serum albumin (4.7










l/min for the duration of an experiment to maintain hematocrit
and plasma protein concentration at presurgical levels. Midline and
subcostal incisions were used to expose the abdominal aorta and left
kidney. A noncannulating electromagnetic flow probe (1.5 mm cir-
cumference; Carolina Medical Electronics, King, NC) was placed around
the left renal artery to measure renal blood flow. A tapered and
curved PE-10 catheter was introduced into the left femoral artery and
advanced through the aorta until its tip was positioned approximately
1 mm into the left renal artery (26). Placement of the catheter in the
renal artery did not affect renal blood flow. The renal arterial cathe-





antagonists losartan and EXP 3174 (DuPont-Merck Pharmaceutical




 receptor antagonist CGP-42112
(Ciba Geigy Limited, Basel, Switzerland) (6–8). After completion of
surgery, the animals were allowed to stabilize for 1 h before starting
the measurements.
At the end of the stabilization period, indomethacin (5 mg/kg
body wt) was administered intravenously to inhibit cyclooxygenase
activity. Previous studies indicated that this dose of indomethacin





for at least 3 h, as measured by radio-immunoassay (26). Throughout




l/min) of heparinized iso-
tonic saline was administered via the renal arterial catheter. 1 min be-
fore the administration of ANG II, the rate of saline infusion was in-




l/min so that the entire bolus of ANG II could be
delivered to the kidney within 5 s. A Cheminert sample injection




l bolus into the infusion line (Valco
Instruments Co., Houston, TX). Previous studies indicated the bolus
reached the kidney 12 s after its introduction into the infusion line










The following drugs were used: ANG II (Sigma Chemical Co.,
St. Louis, MO), losartan (DuP-753, DuPont-Merck Pharmaceutical
Co., Wilmington, DE), EXP-3174 (DuPont-Merck), PD-123319 (Parke-
Davis Pharmaceutical Co., Ann Arbor, MI), CGP-42112 (Ciba Geigy),
enalaprilat (Merck), and indomethacin (Sigma). ANG II was injected
at the dose of 2 ng into the left renal artery. This dose of angiotensin
produces a reversible transient 50% decrease in renal blood flow (6–8,
26). Various doses of the ANG II receptor antagonists were injected
as a mixture with 2 ng of ANG II. The time interval between injec-
tions was 15 min. The order of doses was randomly selected each day.
To avoid treatment interactions, a single ANG II antagonist was used
in each rat. To evaluate whether consecutive injections of an antago-
nist created an additive buffering effect, ANG II was injected alone at
the beginning, middle, and end of an experiment. In all cases, ANG II
produced a similar decrease in renal blood flow. To test if the buffer-
ing effect of ANG II antagonists was localized to the kidney, ANG II
was injected intravenously before and during intrarenal injections of
the agonists. In both conditions, ANG II caused a similar rise in arte-
rial pressure.
The data acquisition system consisted of an IBM-compatible
computer and a 12 bit A/D converter. The flow probe was interfaced
to the data acquisition system using a Carolina Medical Electronics
500 electromagnetic flowmeter. A Hewlett-Packard 8805B carrier






the transducers monitoring arterial pressure and renal blood flow
were sampled at a rate of 100 samples/s for a period of 2 min, which
usually was sufficient time to allow flow to return to its baseline value
after each injection of ANG II. Each recording was started when
ANG II was introduced into the renal artery infusion line. Consecu-
tive blocks of 100 data points were averaged to obtain second-by-sec-
ond estimates of renal blood flow and arterial pressure, and these av-
erages were used to calculate second-by-second estimates of renal
vascular resistance. The renal blood flow, arterial pressure, and renal
vascular resistance values were normalized and expressed as a per-
cent of baseline values. The baseline was calculated separately for
each injection using the mean values of the corresponding variables
observed during the time between the introduction of ANG II into
the infusion line and the onset of the renal vascular response. Plots of
normalized arterial pressure, renal blood flow, and renal vascular re-
sistance as a function of time were prepared using the SigmaPlot soft-
ware package.
 
Preparation of isolated afferent arterioles.
 
Afferent arterioles from
the rat kidney were isolated by a method of Chatziantoniou and
Arendshorst (6). Acute receptor binding studies were performed on
vascular tissue isolated from male, 7-wk–old euvolemic rats main-
tained on three different levels of sodium diets (0.8, 1.2, and 3.4%)
for 3 wk prior to study. The kidneys were infused with a magnetized








 in saline) for 0.5–1 min at constant
pressure (120 mmHg) and then excised and placed in a phosphate






























C. Cortical tissue was homogenized using a Polytron tis-
suemizer. Renal preglomerular vessels, glomeruli, and the surround-
ing connective tissue were removed from the crude homogenate with
the aid of a magnet. The vascular tissue was passed through needles




m sieve mesh screen to
detach connective tissue, remove iron oxide from the large vessels,
and to separate afferent arterioles from glomeruli. The vascular tissue




m sieve consisting of afferent arteri-




 95%) was used for the subsequent binding













tein) were incubated at room temperature in a final volume of 0.25 ml
buffer containing 0.3% bovine serum albumin (Sigma). Incubations













ANG II (NEN, DuPont, Boston, MA) under continuous gentle shak-
ing. The protein concentration, binding conditions, and time for equi-
librium were determined in preliminary experiments; the results
agreed with those previously reported (6). Bound ligand was sepa-
rated from the free ligand using centrifugation in a sucrose gradient.
0.2 ml of the samples were gently layered over 0.2 ml of assay-binding
buffer containing 20% sucrose in 0.5 ml polyethylene microcentrifuge
tubes, and were centrifuged at 5,000 g for 30 min in a free-angle rotor.
The tubes were then frozen rapidly by insertion into dry ice, and the
tips, containing the bound ligands, and the tops, containing the free
ligands, were assayed in a gamma counter. Nonspecific binding was









ceptor antagonists losartan (DuP 753), EXP 3174, or CGP-42112












]ANG II (0.375 nM). Analyses of





max) and dissociation constant (Kd) (6).
 












-receptor mRNA was measured by RNase
protection assay as described previously (27). Fragments of 298 bp









were cloned into vector pSP65 (Promega-Serva, Heidelberg, Ger-




I, followed by in vitro transcrip-
tion with SP6 RNA polymerase, yielded a 98 bp protected cRNA




 receptor subtypes. Transcripts were continu-








P]GTP (410 Ci/mM, Amersham International,
Little Chalfont, UK) and purified on a Sephadex G50 spin column.
For hybridization, total RNA from the kidneys was dissolved in a buffer



































 probe. RNase di-
gestion with RNase A and T1 was carried out at room temperature
for 30 min and terminated by incubation with proteinase K (0.1 mg/ml













 fragments was purified by
phenol/chloroform extraction, ethanol precipitation, and subsequent
electrophoresis on a denaturing 10% polyacrylamide gel. After auto-








C for 1 d, the band representing a








 fragments was excised from the
gel, and radioactivity was counted with a liquid scintillation counter.













Reverse transcription was used












































l RNasin [40,000 U/ml,




























) and antisense primers (59-CAC
AAT CGC CAT AAT TAT CCT A-39) designed from the cDNA se-
quences common to rat AT1A and AT1B receptors (28, 29). These
primers correspond to regions where no sequence divergence exists
between AT1A and AT1B, and amplify a 305-bp cDNA fragment from
position 723 to 1028 in the AT1A sequence, and from position 630–935
in the AT1B sequence (28, 29). For AT1-PCR, 10 pmol of the respec-
tive primers were mixed with 3 ml of cDNA obtained by the reverse
transcription reaction described above and with 3 ml MgCl2 (25 mM),
15.5 ml DEPC water, 2.5 ml 103 PCR buffer, and 3 ml deoxy [19,2959-
3H]Cystidine 59-triphosphate (1 mCi/ml).
To distinguish between AT1A and AT1B receptor amplification
products, 1.5 ml (25 U/ml) was added to digest 20 ml of the PCR prod-
uct obtained with the AT1 primers. The mixture was incubated for 1 h
at 378C, a period known to be sufficient for complete digestion. The
reaction was terminated at 948C for 2 min. This digestion yielded
fragments that matched the expected sizes of 128 and 177 bp charac-
teristic of AT1A receptors. The digested PCR products were sepa-
rated by polyacrylamide gel electrophoresis, visualized by ethidium
bromide staining, excised from the gel, dissolved in 25 mM periodic
acid, and quantified by liquid scintillation counting.
Rat b-actin cDNA was amplified with the sense primer (59-CCG
CCC TAG GCA CCA GGG TG-39) that spanned over the border of
the second exon and second intron, and the antisense primer (59-
GGC TGG GGT GTT GAA GGT CTC AAA-39) that bound in the
fourth exon (30). These primers identified a 286 bp DNA fragment.
b-Actin was amplified from the same cDNA used for the AT1A/AT1B
or angiotensin II receptor type 2 (AT2) amplification. Because of the
higher abundance of actin mRNA, the cDNA obtained by the RT-
reaction was diluted 1:1000 before adding 3 ml to the actin PCR,
which was then performed under the same conditions as for AT1 de-
scribed above. The mixtures were heated at 948C for 15 min, and then
cooled on ice. PCR was started by the addition of 1 ml Taq polymerase
(1 U/ml, Boehringer Mannheim) and 1 ml dNTP (25 mM). Denatur-
ing, annealing, and extension reactions were performed at 948C for 1
min, 528C for 1 min, and 728C for 20 s. As was done for the AT recep-
tors, all 20 samples were analyzed in one assay to minimize inter-assay
variability.
PCR products were separated by polyacrylamide gel electro-
phoresis and quantified. PCR products were visualized by ethidium
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bromide staining, excised from the gel, dissolved in periodic acid, and
quantified by liquid scintillation spectrometer. The amounts of PCR
products obtained for AT1A and AT1B receptor mRNA and for b-actin
mRNA, were dependent on the PCR cycle number, and were linear
between 27 to 35 cycles (Fig. 1) (31). Therefore, we used 30 cycles as
the standard protocol for our determinations. To circumvent eventual
contamination of genomic DNA in sample RNAs, direct PCR ampli-
fication of sample RNA without reverse transcriptase was performed
routinely. No significant product was detected for up to 35 cycles.
PCR for AT2 cDNA was carried out by reverse transcription of
mRNA in a manner similar to that described above for AT1 recep-
tors. After PCR reaction with sense (59-CGG GAT CCT TTG ATA
ATC TCA AC- 39) and antisense primers (59 -GGA ATT CAA
ACA CTT TGC CAT CAC- 39), a 315-bp fragment was amplified
(32). Primers were designed with a BamHI site at the 59 and a EcoRI
site at the 39 end for possible cloning experiments. Conditions for
AT2 PCR were as follows: 35–37 cycles with 30 s heating at 948C were
followed by a 1 min annealing step at 558C and 30 s polymerization at
728C. Previous studies showed linearity of the PCR reaction from 31
up to 37 cycles under these conditions (31).
Statistical methods. Statistical analyses were performed using a
SigmaStat software package. Comparisons between two groups were
analyzed using Student’s unpaired t test. Larger data sets were tested
with analysis of variance. Results with P , 0.05 were considered sta-
tistically significant. All values reported are means6SE.
Results
Baseline renal hemodynamic data are summarized in Table I.
Experiments were performed on 7-wk–old animals that
weighed z 220 g. Animals maintained for 3 wk on either low-
or high-sodium diets had similar values for mean arterial pres-
sure, renal blood flow, and renal vascular resistance.
To evaluate effect of sodium intake on renal vascular reac-
tivity, a bolus of ANG II (2 ng) was injected into the renal ar-
tery to elicit a transient decrease in renal blood flow. The ani-
mals were acutely treated with indomethacin to minimize
ANG II interactions with vasoactive cyclooxygenase metabo-
lites. Fig. 2 summarizes the group averages for the pattern of
transient response to bolus injection of ANG II. The maxi-
mum renal vasoconstriction produced by ANG II was signifi-
cantly reduced in the low-sodium group compared with re-
sponses in the high-salt animals (1662 vs. 5664% decrease in
renal blood flow, P , 0.001). Similar group differences were
noted in absolute changes in renal blood flow. Arterial pres-
sure was unaffected by the intrarenal injection of ANG II.
Thus, the decreases in renal blood flow were mirrored by re-
ciprocal increases in renal vascular resistance (data not
shown).
To identify mediation of effects by ANG II receptor sub-
types, the AT1 receptor antagonist losartan was injected into
the renal artery simultaneously with ANG II. The maximum
ANG II-induced renal vasoconstriction was identified as a
100% response, and responses in low- and high-sodium groups
were normalized to the maximum responses in their respective
groups. As shown in Fig. 2, losartan inhibited the maximum
decrease in renal blood flow in a dose-dependent manner.
Clearly a large amount of this AT1 receptor antagonist inhib-
ited the majority of the renal vasoconstriction. The apparent
maximum inhibition by 10 mg losartan was about 80% of the
renal response to ANG II (Fig. 3). This was the case for the
normalized response in animals maintained on either low- or
high-sodium diet. This observation is consistent with previous
results for rats on a normal salt diet (6). Similar results were
obtained when EXP-3174 was used to antagonize ANG II
binding to AT1 receptors. Increasing doses of EXP-3174
caused dose-dependent inhibition of ANG II effects. The same
degree of inhibition was noted in rats on low- and high-sodium
diets. Maximum inhibition was up to 90–95% of the ANG II-
induced renal vasoconstriction (data not shown).
The AT2 receptor antagonist CGP-42112 was much less ef-
fective (Fig. 3). Intrarenal injection of 1,000 ng CGP-42112
with 2 ng ANG II blunted less than 5% of the ANG II-induced
renal vasoconstriction. The high doses of 5 and 10 mg CGP-
42112 blocked up to 30% of the renal hemodynamic response
to ANG II. No differences were noted between sodium diet
groups.
To evaluate the influence of endogenous levels of ANG II
on vascular reactivity to administered ANG II, paired experi-
ments were conducted in four low-sodium animals before and
after intravenous injection of enalaprilat to inhibit angio-
tensin-converting enzyme (ACE). In the control period ANG
II (2 ng) reduced blood flow by about 20%, as compared to a
40% decrease after administration of enalaprilat in animals
consuming a low sodium diet. The twofold increase in vascular
reactivity to the standard dose of ANG II after acute inhibition
of ACE was significant (P , 0.02). Losartan inhibited up to
80% of the renal vasoconstriction produced by exogenous
Figure 1. Dependence of amounts of AT1A and AT1B cDNA on PCR 
cycle number between 27 and 35 cycles.
Table I. Renal Hemodynamics in Euvolemic 7-Wk–Old Rats 
Maintained on Low- or High-Sodium Diets for 3 Wk
Low-sodium diet High-sodium diet
n 5 20 n 5 19
Age (wk) 761 761
Body wt (g) 22466 21169
Mean arterial pressure (mmHg) 13163 13263
Renal blood flow
(ml·min21·min·g kidney wt21) 8.360.5 7.860.4
Renal vascular resistance
(mmHg·m21·min·g kidney wt) 16.360.8 17.860.9
Hematocrit (ml·dl21) 47.360.9 47.560.6
Values are means6SE. There were no statistically significant (P . 0.05)
differences between dietary groups.
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ANG II whether or not ACE was blocked. In this regard, inhi-
bition of ANG II production by enalaprilat converted the re-
sponses to exogenous ANG II to a pattern previously reported
for rats maintained on their standard diet (6–8, 26). Thus, part
of the attenuated vascular reactivity to exogenous ANG II
could be attributed to prior receptor occupation by endoge-
nous ligand.
In other studies, we determined ANG II receptor charac-
teristics in preglomerular resistance vessels. Biochemical satu-
ration ligand binding studies were performed on freshly iso-
lated afferent arterioles from rats maintained on different
sodium diets for 3 wk. Representative examples of ANG II
binding under equilibrium conditions are presented in Fig. 4.
Scatchard analysis revealed one predominant class of high af-
finity receptor in low-, normal-, and high-sodium diet groups
(Hill coefficient 5 0.9–1.0 for all groups). As the data in Table
II show, there was no difference in the value of dissociation
constant between the low- and high-sodium groups (Kd 5 0.5
vs. 0.8 nM). On the other hand, there was a large almost two-
fold difference in receptor density (Table II). Animals con-
suming the high-sodium diet had about twice as many receptor
sites as the low-sodium animals (Bmax 5 298 vs. 158 fmol/mg).
These results indicate that ANG II binding to afferent arteri-
oles is regulated in response to variations in salt intake and ac-
tivity of the renin–angiotensin system. Changes in receptor
density probably participated in the observed differences in re-
nal vascular reactivity to ANG II in sodium diet groups.
Other in vitro binding studies were performed to evaluate
the effect of sodium diet on ANG II receptor subtype(s) ex-
pressed in this vascular preparation. Unlabeled ANG II, the
AT1 receptor antagonists losartan and EXP-3174, and the AT2
ligands PD-123319 and CGP-42112, were used to displace
0.375 nM 125I-ANG II from binding sites. The data are pre-
sented in Fig. 5, top and bottom panels, respectively. Ex-
pressed as a percent of ANG II specific binding, there were no
Figure 2. Dose-dependent inhibition by the AT1 receptor antagonist 
losartan of angiotensin II-induced reductions in renal blood flow in 
rats consuming a low- or high-sodium diet for 3 wk prior to study. 
Angiotensin II was injected into the renal artery alone and in combi-
nation with different amounts of losartan. Means6SE for 20 low-salt 
rats and 19 high-salt animals.
Figure 3. Summary of dose-dependent inhibition of the maximum 
angiotensin II-induced renal vasoconstriction produced by injection 
of either losartan or CGP-42112 simultaneously with angiotensin II. 
Means6SE for more than five animals in each group.
Figure 4. Representative examples of 125I-angiotensin II binding to 
freshly isolated afferent arterioles obtained from rats on low-, nor-
mal-, and high-sodium intakes. Saturation binding curves are shown 
in left panel. Scatchard analysis is presented in the right panel.
Regulation of Afferent Arteriolar AT1 Receptors by Salt Diet 1077
major differences between the two groups on different sodium
diets. Competitive inhibitory potencies of these agents showed
ANG II . EXP-3174 $ losartan .. CGP-42112 $ PD-123319.
Table III summarizes the Ki values for each compound. Losar-
tan was about two times less potent than EXP-3174 ligands
(P , 0.002 for both diet groups), and more than ten times
more potent that AT2 receptor ligands. The Hill coefficient for
losartan was less than unity for low- (0.7560.02, P , 0.001)
and high-sodium diets (0.8060.03, P , 0.005), suggesting
negative cooperativity, or multiple, noninteracting binding
sites. In agreement with our previous findings (6), the most
abundant ANG II binding sites showed high affinity for losar-
tan, with a Ki of 37 nM; this class accounted for up to 80% of
the total population. The low-affinity site for losartan occupied
the remaining 20% of the total ANG II receptor site with an
1,000-fold lower affinity than the majority, high affinity site.
The AT2 receptor analogue PD-123319 and CGP-42112 dis-
placed 125I-ANG II binding only at extremely high concentra-
tions (5–10 mM). There was no statistically significant displace-
ment when the AT2 ligand’s concentration was less than 1 mM
(P . 0.1).
ANG II receptor gene expression was determined to ex-
plore the mechanism by which altered activity of the renin–
angiotensin system (due to sodium diet) regulated ANG II re-
ceptor density. ANG II receptor mRNA levels in the afferent
arterioles were determined by RNase protection assay. These
resistance vessels expressed two, and perhaps three, subclasses
of the ANG II receptors. Expression of AT1A and AT1B were
clearly discernible (Fig. 6, top panel). The AT1 receptor is the
predominant subtype, whereas the AT2 receptor message
showed a much weaker signal. The AT2 receptor mRNA rela-
tive to that of AT1 was considerably less (z 50–100 times less)
and more difficult to document with any certainty. RT-PCR
Table II. Characteristics of ANG II Receptor Binding in 
Afferent Arterioles Freshly Isolated From Kidneys of
7-Wk-–Old Rats Maintained on Different Sodium Diets
for 3 Wk





Values are means6SE of 3 experiments per group (4 rats/experiment).
*P , 0.05 vs. low sodium diet.
Figure 5. Summary of displacement of 125I-angiotensin II from 
freshly isolated afferent arterioles by unlabeled angiotensin II, AT1 
receptor antagonists (losartan and EXP-3174) and an AT2 receptor 
ligands (PD-123319 and CGP-42112). Each curve is based on three or 
more experiments.
Table III. Inhibitory Constant (Ki) Values for Peptide and 
Nonpeptide Antagonists in Displacing 125I-ANG II (0.375 nM) 




ANG II 6.061.0 4
Exp 3174 9.561.5 9
Losartan 3763.0‡ 10
CGP 42112 4906141*§ 6
PD-123319 . 10,000 7
Values are means6SE. n 5 number of experiments; 4 rats/experiment.
There were no differences between sodium diets, so the data were
pooled. *P , 0.05 vs. ANG II, ‡P , 0.001 vs. ANG II, §P , 0.05 vs.
losartan.
Figure 6. RT-PCR analysis of AT receptor cDNA in freshly isolated 
afferent arterioles. AT1A and AT1B receptor cDNA was evident at 30 
cycles. An AT2 receptor cDNA was detected at 37 cycles.
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analysis of the afferent arteriole eventually revealed the exist-
ence of an AT2 mRNA signal. At least 35 cycles were required,
however, as compared to a signal of similar strength for AT1
mRNA with fewer than 30 cycles (Fig. 6, bottom).
Compared to the control diet, stimulation of the renin–
angiotensin system by low-sodium diet decreased total AT1
mRNA levels by 34%, but increased levels about 32% when
the renin–angiotensin system was inhibited by high sodium in-
take. As is presented in Fig. 7 (top), quantitative assessment of
total AT1 mRNA levels in afferent arterioles by the RNase
protection assay show that the changes in expression corre-
lated with diet treatment. There was an approximate doubling
of expression in high- vs. low-sodium diet. There was a close
correlation between changes in AT1 mRNA and ANG II re-
ceptor density in the three diet groups (Fig. 7, top). Both mea-
sures of receptor expression paralleled each other, exhibiting a
twofold difference between low- and high-sodium diets.
To ascertain which AT1 subtype was regulated during
changes in sodium balance, the relative expression of AT1A
and AT1B was analyzed by RT-PCR. The data show that
mRNA for both AT1A and AT1B increased in parallel with di-
ets of increasing sodium content (Fig. 7, bottom). Message for
both subtypes increased twofold when high- and low-sodium
diets are compared. The ratio of AT1A/AT1B mRNA averaged
about 3.7, and was stable among different diet groups. Thus,
the AT1A is primary receptor subtype expressed in the smallest
preglomerular arterioles. Comparing the results in the lower
with the upper panel in Fig. 7 demonstrates that the changes
in both AT1A and AT1B expression were directly related to
changes in total AT1 mRNA and ANG II binding sites in re-
sponse to salt diet induced changes in renin-angiotensin activity.
Discussion
The present study provides new information about the expres-
sion and function of AT1 receptor subtypes in the small diame-
ter afferent arteriole, a resistance vessel that contributes signif-
icantly to the vascular response to ANG II in the kidney. Our
investigation presents a comprehensive evaluation of receptor
function incorporating molecular expression of mRNA, bio-
chemical receptor characterization in isolated vascular smooth
muscle cells, and functional assessment of vascular reactivity
to receptor stimulation in vivo. Our blood flow results clearly
demonstrate that the regulation of renal vascular reactivity
varies directly with sodium intake, and indirectly with activity
of the renin–angiotensin system. The chronic adjustments in
vascular responsiveness to ANG II depend on at least three
underlying mechanisms: receptor expression, receptor protein
density, and prior receptor occupation by endogenous ANG
II. PCR and RNase protection assays establish that the AT1A
subtype is the predominant receptor in the afferent arteriole,
and that changes in AT1 receptor expression were accompa-
nied by parallel regulation of AT1A and AT1B mRNA. In con-
trast, the AT2 receptor is weakly expressed and is unaffected
by salt diet. In vitro biochemical radioligand binding studies
performed on freshly isolated afferent arterioles and interlob-
ular arteries indicate increased ANG II receptor density with
unchanged affinity during sodium loading. The opposite ef-
fects were elicited by activation of renin–angiotensin activity
by a chronic low-sodium diet: mRNA for AT1A and AT1B re-
ceptors, ANG II receptor density, and vascular reactivity were
downregulated in response to sodium deprivation.
Our animal blood flow studies confirm previous observa-
tions in the rat and other species including humans. Although
vascular reactivity is known to vary in proportion to salt diet,
the precise mechanisms mediating the changes are not clear.
Renal blood flow studies indicate that the vascular response to
exogenous ANG II is depressed in low-sodium diet rats, and
enhanced in sodium-loaded animals (Fig. 2) (9). Part of the
acute response to administered ANG II is modulated by high
endogenous ANG II levels when the renin–angiotensin system
is stimulated by low sodium diet. This was shown by adminis-
tering enalaprilat acutely to block angiotensin-converting en-
zyme and subsequent production of ANG II. After suppres-
sion of endogenous ANG II formation, exogenous ANG II
produced larger changes in renal blood flow in low-salt rats.
Earlier studies had demonstrated that angiotensin-converting
enzyme inhibition increased the systemic pressor effect of
ANG II during sodium restriction, whereas only a small
Figure 7. (A) The effect of chronic salt diet on the total AT1 receptor 
mRNA expression normalized to GAPDH mRNA as determined by 
ribonuclease protection assay in afferent arterioles in groups consum-
ing different sodium diets. There were parallel changes in ANG II re-
ceptor density in radioligand binding studies on afferent arterioles 
isolated from kidneys of rats consuming a low, normal, or high salt 
diet. Means6SE for three experiments in each group. (B) Changes in 
AT1A and AT1B mRNA in afferent arterioles as a function of sodium 
diet. Subtype levels were calculated from total AT1 receptor mRNA 
determined by RNase protection assay and the ratio of AT1A to AT1B 
mRNA assayed by semiquantitative RT-PCR. Means6SE for three 
experiments in each group. *Represents statistically significant dif-
ference between low- and high-salt groups.
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change occurred in the salt-loaded rats (33). Thus, endogenous
levels of ANG II contribute importantly to the difference in
renal vascular reactivity to a standard dose of exogenous ANG
II observed between animals on low- and high-salt intakes.
Our studies provide new information about the relative dis-
tribution of ANG II receptor subtypes in the afferent arteriole,
and their regulation in response to differing salt intake. We
present evidence demonstrating that the predominant subtype
in the afferent arteriole from kidneys of 7-wk–old rats is the
AT1A receptor, with a ratio of AT1A to AT1B receptor mRNA
of almost 4. This compares with a ratio of 3 for renal tissue in
general, and a ratio of 2 for aortic smooth muscle (34, 35). On
the other hand, AT2 receptor expression is considerably lower.
Previous studies show that AT1 mRNA is preferentially ex-
pressed in the rat kidney, and is found in glomeruli, juxtaglo-
merular cells, and epithelial cells (2, 21, 35–38). There is less
convincing genetic evidence that the AT1 receptor is localized
to preglomerular resistance vessels or the afferent arteriole in
particular. Several investigators failed to find significant ex-
pression of AT1 receptors in preglomerular arteries and arteri-
oles and efferent arterioles other than the localized region of
juxtaglomerular cells (37, 39). On the other hand, radioligand
binding data clearly demonstrate significant ANG II binding
to AT1 receptors that are antagonized by losartan in large and
small preglomerular arteries and arterioles (Fig. 5) (6, 14, 40).
Both afferent and efferent arterioles show a high density of
AT1 receptors when localized using antiserum directed against
the NH2 terminus of the receptor (41).
Two sets of our results indicate an increase in AT1 receptor
density in afferent arterioles of animals fed a high-salt diet.
Our radioligand binding studies provide new information
about renal resistance vessels, and demonstrate a Bmax value
that is twofold larger during sodium loading. These findings
are reinforced by results obtained using a RNase protection as-
say which indicates that total AT1 mRNA expression was two-
fold greater in animals on a high-sodium diet. Our results for
vascular reactivity in vivo lend further support to this view. We
observed a similar degree of antagonism of AT1 receptor by
losartan and EXP-3174 in vessels isolated from low- and high-
salt rats after the data were normalized for differences in total
density. These new observations for the afferent arteriole
agree with and extend previous results for renal glomeruli and
nonrenal vascular smooth muscle cells. Activation of the re-
nin–angiotensin system by low-sodium diet reduces the density
of ANG II receptors in glomeruli, cultured mesangial cells,
and mesenteric artery (12, 16, 19, 21, 42–44). A role for ANG
II has been demonstrated by studies utilizing chronic infusions
of ANG II and by chronic inhibition of ANG production using
an ACE inhibitor (16, 19). Some reports, however, describe
unresponsive glomerular receptors to low- and high-salt diets,
and to administration of ANG II (14). Conflicting results also
have been found in cultured rat glomerular mesangial cells. In
one case, AT1 mRNA was downregulated following an in-
crease in ANG II, and the effect was antagonized by losartan
(25). On the other hand, there are reports that ANG II has no
effect on AT1 receptor expression in the rat kidney or in hu-
man mesangial cells (24, 45).
Few studies have addressed the interesting question of AT1
receptor subtype regulation in discrete cell types in the kidney.
We observed that the ratio of AT1A and AT1B receptor mRNA
in afferent arteriolar smooth muscle cells is unchanged by so-
dium dietary treatment. This results from parallel regulation of
message for both receptors in the afferent arteriole in response
to changes in salt diet and renin–angiotensin activity (Fig. 7).
A recent study suggests that one subtype may be regulated in-
dependently of another. Sodium deprivation was found to
cause an increase in AT1A and a decrease in AT1B mRNA at
the whole kidney level (46). In another report, Northern blot
analysis showed that AT1A mRNA in renal tissue was in-
creased by losartan treatment in normal and sodium-restricted
animals (23). Results obtained by renal cortex or entire kidney
tissue, however, should be interpreted with caution because of
probable differential regulation in the multiple cells types. As
a case in point, there are major differences in the regulation of
AT receptors in vessels and tubules in the kidney. In contrast
to the renal vasculature (8, 21, 25, 47), increased ANG II levels
are associated with upregulation of AT1 mRNA and ANG II
receptor density in proximal tubular cells and isolated basolat-
eral membranes, and also in the adrenal gland (2, 18, 21–23).
The present radioligand binding results provide another
line of evidence for regulation of AT1 receptors in the afferent
arteriole. Afferent arterioles in rats maintained on low- or high-
sodium diets, as well as those fed a standard, express AT1
receptors antagonized by losartan (Fig. 5) (6). In all of the
dietary groups, 80–90% of the ANG II binding sites display
high affinity to AT1 antagonists. Losartan also is reported to
displace ANG II binding in larger preglomerular arteries
(. 100 mm) in normal rats (14, 40). The present study confirms
previous reports from our laboratory showing that AT2 recep-
tor antagonists do not displace ANG II from vascular binding
sites, and that they fail to affect the renal vasoconstriction elic-
ited by ANG II in rats maintained on their standard sodium
diet (6). The function of ANG II AT2 receptor is unknown, but
some studies found that AT2 sites are abundant in rat fetus,
suggesting that AT2 receptors play a role during development
(5, 48, 49). Other studies suggest AT1 receptor(s) are critical to
normal growth and development (48, 50).
Our blood flow results agree well with our receptor binding
studies. As previously noted for animals on normal salt diet
(6), the AT1 receptor antagonist losartan inhibited up to 80%
of the ANG II-induced renal vasoconstriction in vivo and 80%
of the binding to isolated afferent arteriolar segments. Aside
from the difference in absolute receptor number, percentage
changes in inhibition of ANG II binding and vasoconstriction
were similar in rats maintained on low- or high-sodium diets
for 3 wk. Based on our earlier blood flow studies and ligand
binding experiments, it is reasonable to conclude that losartan
preferentially binds to and antagonizes the AT1 receptor sub-
type in the afferent arteriole (6). The specific functions of
AT1A and AT1B receptors in cells that normally express them
in rodents is not known. Almost all known ANG II effects are
thought to be mediated by the predominant receptor type, the
AT1 receptor, with a tacit assumption that physiological re-
sponses are caused largely if not exclusively mediated by the
AT1A subtype. Currently available pharmacological ligands,
however, do not distinguish between AT1 receptor subtypes.
Recent studies on mice with the AT1A receptor mutated by
gene targeting suggest that the AT1B as well as the AT1A recep-
tor may play a role in blood pressure control (51).
In summary, our data demonstrate the existence of two
subtypes of AT1 receptors, AT1A and AT1B in small-diameter,
preglomerular renal resistance vessels. The AT1A subtype is
predominant with expressed levels almost four times greater
than those of the AT1B receptor mRNA in the afferent arteri-
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ole. In contrast, there is a paucity of AT2 receptors. Regulation
of ANG II AT1 receptor mRNA expression is associated with
a change in sodium diet and presumed activity of the renin–
angiotensin system. Variations in sodium intake produce simi-
lar changes in the AT1 receptor in renal resistance vessels as
evidenced by parallel message changes for AT1A and AT1B re-
ceptors during up and downregulation in response to salt diet.
Changes observed in the binding density of ANG II receptors
agreed well with those in total AT1 expression; both indicated
a twofold increase in high-sodium vs. low-sodium rats. A
larger difference was suggested in blood flow studies, as the re-
nal vasoconstriction elicited by administered ANG II was
three to four times greater in the high-salt animals. After acute
blockade of ANG II production by an angiotensin converting
enzyme inhibitor, however, the ANG II-induced renal vaso-
constriction increased in animals with an activated renin-
angiotensin system such that the difference between groups
was reduced to about 1.5 times. Thus, there was a close corre-
lation between AT1 receptor mRNA, AT1 binding sites, and
renal blood flow responses to injected ANG II during varia-
tions in sodium diet. Sodium restriction produces a reduction
in ANG II AT1 mRNA level, translating into reduced receptor
protein synthesis, with the decreased density of cell surface
binding sites responsible for attenuated vascular reactivity to
administered ANG II.
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